DRUGS, MONEY, AND SECRET HANDSHAKES: THE UNSTOPPABLE GROWTH OF PRESCRIPTION DRUG PRICES (Cambridge University Press 2019).
DRUG WARS: HOW BIG PHARMA RAISES PRICES AND KEEPS GENERICS OFF THE MARKET (Cambridge Univ. Press 2017) (with Evan Frondorf).
RETHINKING PATENT LAW (Harvard Univ. Press 2012).
THE ROLE OF SCIENCE IN LAW (Oxford Univ. Press 2009).
Journal Articles
Paucity of intellectual property rights information in the US biologics system a decade after passage of the Biosimilars Act, 21 PLoS Med. (4) (2024).
Insulin: California’s Initiative to Enter the Insulin Market, JAMA Internal Med. (2023).
CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market, 183 JAMA Internal Med. 1043 (2023).
Link
Advertising Medicine: Selling the Cure, 26 Stan. Tech. L. Rev. 1 (2023).
Link, SSRN
Leading With the Trailing Edge: Facilitating Patient Choice for Insulin Products, 10 J. L. & Biosci. 1 (2023).
SSRN
Patents as Property for the Takings, 12 N.Y.U. J. Intell. Prop. & Ent. L. 198 (2023).
Link, SSRN
CalRx Biosimilar Insulin: California’s Initiative to Enter the Insulin Market, 183 JAMA Internal Med. 1043 (2023).
Challenges with Defining Pharmaceutical Markets and Potential Remedies to Screen for Industry Consolidation, 47 J. Health Pol. Pol’y & L. 583 (2022) (with Brent D. Fulton; Jamie R. Godwin & Richard M. Scheffler).
Link
A Patient Price Guide for Prescription Medication, 175 Annals Internal Med. 885 (2022) (with Natalie Feldman & Enrique Seoane-Vazquez).
Trade Secrets in Biologic Medicine: The Boundary with Patents, 24 Colum. Sci. & Tech. L. Rev. 1 (2022).
Link, SSRN
The Price Tag of ‘Pay-for-Delay’, 23 Colum. Sci. & Tech. L. Rev. 1 (2022).
Link, SSRN
Designing Disruption in Pharmaceuticals, 28 B.U. J. Sci. & Tech. L. 1 (2022).
Link, SSRN
Captive Generics: The Wolf in Sheep’s Clothing, 59 Harv. J. on Legis. 383 (2022).
Link, SSRN
Understanding “Evergreening”: Making Minor Modifications Of Existing Medications To Extend Protections, 41 Health Aff. 801 (2022).
Combination Therapy Patents: A New Front in Evergreening, 39 Nature Biotech. 1504 (2021) (with Garth W. Strohbehn; Alec J. Kacew; Daniel A. Goldstein & Mark J. Ratain).
Link
The Devil in the Tiers, 8 J. L. & Biosci. 1 (2021).
Link
AI Governance in the Financial Industry, 27 Stan. J.L. Bus. & Fin. 94 (2021) (with Kara Stein).
Link
Negative Innovation: When Patents Are Bad for Patients, 39 Nature Biotech. 914 (2021) (with David A. Hyman et al.).
Link
The Arc of History in Patent Subject Matter, 11 Hastings Sci. & Tech. L.J. 1 (2020).
Link
Startups and Unmet Legal Needs, 2016 Utah L. Rev. 575 (2016) (with Alice Armitage; Evan Frondorf; and Christopher Williams).
Link, SSRN
Regulatory Property: The New IP, 40 Colum. J.L. & Arts 53 (2016).
Link, SSRN
The CRISPR Revolution: What Editing Human DNA Reveals About the Patent System’s DNA, 64 UCLA L. Rev. Disc. 392 (2016).
Link, SSRN
Patent Licensing, Technology Transfer and Innovation, 106 Am. Econ. Rev. 188 (2016) (with Mark A. Lemley).
SSRN
Federalism, First Amendment & Patents: The Fraud Fallacy, 17 Colum. Sci. & Tech. L. Rev. 30 (2015).
Link, SSRN
Do Patent Licensing Demands Mean Innovation?, 101 Iowa L. Rev. 137 (2015) (with Mark A. Lemley).
Link, SSRN
The AIA 500 Expanded: Effects of Patent Monetization Entities, 17 UCLA J.L. & Tech. 1 (2013) (with Tom Ewing & Sara Jeruss).
Copyright at the Bedside: Should We Stop the Spread?, 16 Stan. Tech. L. Rev. 623 (2013) (with John Newman).
Link, SSRN
A Conversation on Judicial Decision-Making, 5 Hastings Sci. & Tech. L.J. 1 (2013).
Link, SSRN
The America Invents Act 500: Effects of Patent Monetization Entities on US Litigation, 11 Duke L. & Tech. Rev. 357 (2012) (with Sara Jeruss & Joshua H. Walker).
SSRN
The Giants Among Us, 2012 Stan. Tech. L. Rev. 1 (2012) (with Tom Ewing).
Link, SSRN
Understanding and Incentivizing Biosimilars, 64 Hastings L.J. 57 (2012) (with Jason Kantor).
Link, SSRN
Whose Body Is It Anyway? Human Cells and the Strange Effects of Property and Intellectual Property Law, 63 Stan. L. Rev. 1377 (2011).
Link, SSRN
Copyright and Open Access at the Bedside, 365 New Eng. J. Med. 2449 (2011) (with John Newman).
The Intellectual Property Landscape for iPS Cells, 3 Stan. J.L. Sci. & Pol’y 16 (2010) (with Deborah Furth).
Link, SSRN
The Role of the Subconscious in Intellectual Property Law, 2 Hastings Sci. & Tech. L.J. 1 (2010).
Link, SSRN
Historic Perspectives on Law & Science, 2009 Stan. Tech. L. Rev. 1 (2009).
Link, SSRN
Law’s Misguided Love Affair with Science, 10 Minn. J. L. Sci. & Tech. 95 (2009).
Link, SSRN
Intellectual Property: Naked Price & Pharmaceutical Trade Secret Overreach, in 5 The Judges’ Book 93 (Scott Dodson ed., UC Hastings 2021).
Competition at the Dawn of Artificial Intelligence, in Competition Law for the Digital Economy 71 (Björn Lundqvist & Michal S. Gal eds., Edward Elgar 2019) (with Nick Thieme) (peer reviewed).
Learning from Past Mistakes – The US Patent System and International Trade Agreements, in Megaregionalism 2.0: Trade and Innovation within Global Networks 145 (Dieter Ernst & Michael G. Plummer eds., World Scientific Studies in International Economics 2018).
Coming to the Community, in Imagining New Legalities: Privacy and Its Possibilities in the 21st Century 84 (Austin Sarat et al.eds., Amherst Series in Law, Jurisprudence & Social Thought, Stanford Univ. Press 2012).
Patent Misuse: From Inception to Modern Case Law, in 2 Intellectual Property and Information Wealth: Issues and Practices in the Digital Age 137 (Peter K. Yu ed., Praeger Publishers 2007).
Book Reviews
Book Review, 34 Governance 263 (2021) (reviewing GERALD POSNER, PHARMA: GREED, LIES, AND THE POISONING OF AMERICA).
For the Love of Licensing, 18 Va. J.L. & Tech. 178 (2013) (reviewing CYNTHIA CANNADY, TECHNOLOGY LICENSING AND DEVELOPMENT AGREEMENTS).
Newspaper & Magazine Articles
Cutting-Edge Insulin is Good. But it’s the ‘Trailing Edge’ of Older Versions That Can Keep it Affordable, Wash. Post, May 15, 2024.
Link
The Problem with Direct-to-Consumer Pharmaceutical Advertising, Wash. Post, Mar. 2, 2023.
Link
We Need a Labeling System for Pharmaceutical Prices, Wash. Post, Jun. 10, 2022 (with Natalie Feldman & Enrique Seoane-Vazquez).
Drug Companies Keep Merging. Why That’s Bad for Consumers and Innovation, Wash. Post, Apr. 6, 2021.
What Is the Price of a Prescription Drug?, Promarket, Feb. 4, 2021.
Our Patent System is Broken. And it Could Be Stifling Innovation, Wash. Post, Aug. 8, 2021 (Op-Ed).
Why the Cancer “Moonshot” Has Been So Disappointing, Wash. Post, Sep. 14, 2019.
The Perils of Value-Based Pricing for Prescription Drugs, Wash. Post, Apr. 11, 2019.
‘One-and-Done’ for New Drugs Could Cut Patent Thickets and Boost Generic Competition, STAT, Feb. 11, 2019.
Why Prescription Drug Prices Have Skyrocketed, Wash. Post, Nov. 26, 2018.
How Big Pharma Is Hindering the Treatment of the Opioid Addiction Epidemic, The Conversation, Aug. 7, 2017.
Next Patent Troll Victims: Pharma & Bio?, The Hill, Mar. 28, 2014.
Slowing the Patent Trolls, N.Y. Times, Mar. 28, 2014.
FTC Must Move Quickly Against Patent Trolls, S.F. Chron., 21-Jul 2013.
You Patented It, You Own It? Not So Fast, Bos.Globe, Jan. 20, 2013.
Shedding Light on ‘Prometheus’, 10 The Recorder, Mar. 9, 2012.
Miscellaneous
Incentivizing Failure, UC Hastings Research Paper (2021).
Pharmaceutical Pipeline Divestitures Study: Preliminary Results, UC Hastings Research Paper (2021).
States’ Rights: A Patent Law Analysis of NASHP Rate-Setting Model Act, National Association of State Health Policy White Paper (Mar-18 2018) (with Betty Chang Rowe, Rabiah Oral. Amy Y. Gu, & Katherine Gudiksen).
Comment on the Food and Drug Administration (FDA) Notice: Administering the Hatch-Waxman Amendments, Ensuring a Balance Between Innovation and Access, (Sept. 18, 2017).
Learning from Past Mistakes – The US Patent System and International Trade Agreements, Working Paper, East-West Center Workshop on Mega-Regionalism – New Challenges for Trade and Innovation (2016).